4D Molecular Therapeutics FDMT Enterprise value

Enterprise value at other companies

Eli LillyLLY

$1.12T+51.8%

Regeneron PharmaceuticalsREGN

$65.61B+15.0%

Vertex PharmaceuticalsVRTX

$120.2B+7.2%

EyePoint, Inc.EYPT

$1.11B+90.1%

AbbVieABBV

$460.96B+24.7%

RegenxbioRGNX

$651.8M+51.8%

FAQ

What is 4D Molecular Therapeutics's enterprise value?

4D Molecular Therapeutics (FDMT) reported enterprise value of $423.34M in Q1 2026.

How has 4D Molecular Therapeutics's enterprise value changed year-over-year?

4D Molecular Therapeutics's enterprise value increased by 961.4% year-over-year, from $39.88M to $423.34M.

What is the long-term trend for 4D Molecular Therapeutics's enterprise value?

Over 5 years (2020 to 2025), 4D Molecular Therapeutics's enterprise value has grown at a -14.4% compound annual growth rate (CAGR), from $847.68M to $389.69M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.